http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국여성에서 자궁내막증의 발생위험도와 Estrogen Receptor-α 유전자 다형성과의 관련성에 관한 연구
이사라,허성은,문혜성,김형래,정혜원 이화여자대학교 의과대학 2003 EMJ (Ewha medical journal) Vol.26 No.2
Objectives: To investigate whether polymorphism of gene encoding estrogen receptor-a is asso-ciated with the risk of endometriosis in Korean women. Material and Methods :We investigated 136 patients with histopathologically confirmed endo-metriosis rAFS stage III/IV and 251 control group women who were surgically proven to have no endometriosis. Polymerase chain reaction(PCR) and restriction fragment length polymorphism (RFLP) of PCR products were done to determine each participant's estrogen receptor-a genotype. Results : The distridution according to PvuII genetic polymorphism of estrogen receptor-a were as follows. PP, Pp and pp were 14.7%(20 women), 39.0%(53 women) and 46.3%(63 women) in the study group and 13.9%(35 women), 38.6%(98 women) and 47.4%(119 women) in the con-trol group, respectively. There was no significant difference between the study group and the control group. Conclusion : The results suggest that estrogen receptor-a genetic polymorphism may not be associated with the development of endometriosis in Korean women. 목적: 자궁내막증은 에스트로겐에 의존적인 질환이므로 에스트로겐의 합성, 대사 및 작용에 관여하는 유전자의 다형성이 자궁내막증의 발생기전에 중요한 역할을 할 수 있다. 이에 본 연구에서는 한국인 여성에서 에스트로겐 수용체-a의 유전자 다형성이 자궁내막증의 발생 위험도를 증가시키는 지에 대해 연구하고자 하였다. 방법: 1996년 9월부터 2003년 8월가지 본원 산부인과에서 수술을 통해 병리조직학적으로 자궁내막증 III기와 IV기를 확인한 한국인 여성 136명을 대상으로 하였다. 대조군은 자궁내막증 환자군과 연령이 비슷한 만삭 산모에서 제왕절개술을 시행하거나 양성 난소낭종으로 수술을 시행 하였을 때, 자궁내막증이 없음을 확인한 여성 251명 으로 하였다. 결과: ER-a 유전자의 PvuII 다형성의 분포는 자궁내막증 환자군에서 PP군이 20명(14.7%), Pp군이 53명(39.0%), pp군이 63명(46.3%) 이었고 대조군에서의 분포는 각각 35명(13.9%), 97명(38.7%), 119명(47.4%)으로 나타났으며 자궁내막증 환자군과 대조군 사이의 유의한 차이는 없었다. Pp, pp형을 가지는 경우가 자궁 내막증 환자의 85.3%(116명), 대조군의 86.1%(216명)로 나타났으며, 이 경우 자궁내막증이 발생할 odds ratio가 0.904(95% CI, 0.519~1.702)로 통계적으로 유의한 차이가 없었다. 결론: 이상의 결과로 볼 때, 한국인 여성에서 자궁내막증의 발생위험과 에스트로겐 수용체 a 유전자 다형성간에 연관성은 없는 것으로 나타났다.
LEE, DAKEUN,YU, EUN JI,HAM, IN-HYE,HUR2, HOON Potamitis Press 2017 Anticancer research Vol.37 No.1
<P>Background: The clinicopathological significance of oncofetal mRNA-binding protein, human insulin-like growth factor II mRNA-binding protein 3 (IMP3), in gastric carcinoma (GC) is not fully understood. Materials and Methods: Tissue microarray blocks with specimens from 346 patients with GC were constructed to evaluate the clinicopathological role of IMP3 expression in GC. These results were validated with an online dataset of 876 patients from the Kaplan-Meier Plotter. Sera from 15 controls and 57 patients with GC were collected in order to compare the levels of serum IMP3 between groups. Results: High expression of IMP3 was significantly associated with poor prognosis. Survival curves from the Kaplan-Meier Plotter showed that high IMP3 expression was significantly related to worse disease-free survival and overall survival. Conclusion: Tissue overexpression of IMP3 might be used as a predictor of advanced disease or lymph node metastasis, and is associated with poorer prognosis in GCs.</P>
( Eun-ji Choi ),( Bon-kwan Koo ),( Eun-hye Hur ),( Ju Hyun Moon ),( Ji Yun Kim ),( Han-seung Park ),( Yunsuk Choi ),( Kyoo-hyung Lee ),( Jung-hee Lee ),( Eun Kyung Choi ),( Je-hwan Lee ) 한국응용약물학회 2023 Biomolecules & Therapeutics(구 응용약물학회지) Vol.31 No.3
Resistance to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is a concerning problem. Polo-like kinase 1 (PLK1) is a key cell cycle modulator and is known to be associated with an activation of the PI3K pathway, which is related to the stabilization of DNA methyltransferase 1 (DNMT1), a target of HMAs. We investigated the effects of volasertib on HMA-resistant cell lines (MOLM/AZA-1 and MOLM/DEC-5) derived from MOLM-13, and bone marrow (BM) samples obtained from patients with MDS (BM blasts >5%) or AML evolved from MDS (MDS/AML). Volasertib effectively inhibited the proliferation of HMA-resistant cells with suppression of DNMTs and PI3K/AKT/mTOR and ERK pathways. Volasertib also showed significant inhibitory effects against primary BM cells from patients with MDS or MDS/AML, and the effects of volasertib inversely correlated with DNMT3B expression. The DNMT3B-overexpressed AML cells showed primary resistance to volasertib treatment. Our data suggest that volasertib has a potential role in overcoming HMA resistance in patients with MDS and MDS/AML by suppressing the expression of DNMT3 enzymes and PI3K/AKT/mTOR and ERK pathways. We also found that DNMT3B overexpression might be associated with resistance to volasertib.
류마티스 관절염 환자에서 hydroxychloroquine에 의한 급성 전신성 발진성 농포증 증례 1예
임혜진 ( Hye Jin Lim ),정지혜 ( Ji Hye Jung ),김민정 ( Min Jeoung Kim ),김정민 ( Jeoung Min Kim ),강혜란 ( Hye Ran Kang ),송윤경 ( Yoon Kyung Song ),허진욱 ( Jin Wuk Hur ),김상훈 ( Sang Hoon Kim ),김은경 ( Eun Kyung Kim ) 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회) 1991 소아알레르기 및 호흡기학회지 Vol.1 No.2
Acute generalized exanthematous pustulosis (AGEP) is characterized by acute nonfollicular sterile pustules on a background of edematous erythema. Hydroxychloroquine (HCQ), an antimalarial drug, widely used to treat rheumatic and dermatologic diseases. HCQ has been reported to be an uncommon cause of AGEP. We report a 60-year-old woman with rheumatoid arthritis requiring the use of HCQ presented fever and erythematous eruption on the trunk with sterile pustules. Leukocytosis and elevated erythrocyte sedimention rate noted on laboratory examination. On the histopathological examination of the skin biopsy specimen showed neutrophilic infiltration and scattered eosinohpils. The lesions were resolved with removal of HCQ. The clinical course was consistent with the diagnosis of AGEP associated with HCQ. We reported a case of typical AGEP associated with HCQ in a patient with Rheumatoid arthritis. The patient presented resolution from cutaneous lesions with withdrawal of culprit drug, without the need of systemic steroid. (Allergy Asthma Respir Dis 2013;1:176-178)
류마티스 관절염 환자에서 hydroxychloroquine에 의한 급성 전신성 발진성 농포증 증례
임혜진 ( Hye Jin Lim ),정지혜 ( Ji Hye Jung ),김민정 ( Min Jeoung Kim ),김정민 ( Jeoung Min Kim ),강혜란 ( Hye Ran Kang ),송윤경 ( Yoon Kyung Song ),허진욱 ( Jin Wuk Hur ),김상훈 ( Sang Hoon Kim ),김은경 ( Eun Kyung Kim ) 대한천식알레르기학회 2013 Allergy Asthma & Respiratory Disease Vol.1 No.2
Acute generalized exanthematous pustulosis (AGEP) is characterized by acute nonfollicular sterile pustules on a background of edematous erythema. Hydroxychloroquine (HCQ), an antimalarial drug, widely used to treat rheumatic and dermatologic diseases. HCQ has been reported to be an uncommon cause of AGEP. We report a 60-year-old woman with rheumatoid arthritis requiring the use of HCQ presented fever and erythematous eruption on the trunk with sterile pustules. Leukocytosis and elevated erythrocyte sedimention rate noted on laboratory examination. On the histopathological examination of the skin biopsy specimen showed neutrophilic infiltration and scattered eosinohpils. The lesions were resolved with removal of HCQ. The clinical course was consistent with the diagnosis of AGEP associated with HCQ. We reported a case of typical AGEP associated with HCQ in a patient with Rheumatoid arthritis. The patient presented resolution from cutaneous lesions with withdrawal of culprit drug, without the need of systemic steroid. (Allergy Asthma Respir Dis 2013;1:176-178)Allergy Asthma Respir Dis 2013;1:176-178)
( Sung Eun Hur ),( Ji Young Lee ),( Hye Sung Moon ),( Hye Won Chung ) 대한산부인과학회 2008 Journal of Womens Medicine Vol.1 No.1
Objective: To investigate the expression of vascular endothelial growth factors (VEGFs) and VEGF receptor 1 and 2 in eutopic endometrium of patients with advanced endometriosis and to understand the role of VEGFs and VEGF receptors in the development of endometriosis. Methods: Endometrial samples were obtained from 65 premenopausal women, 29~44 years of age, undergoing laparoscopic surgery or hysterectomy for non-malignant lesions. Sufficient samples were collected from 33 patients with endometriosis (stages III or IV) and 32 controls without endometriosis, as confirmed by laparoscopic surgery. Expression of VEGFs mRNA and protein and their receptors in the eutopic endometrium were analyzed by RT-QC PCR and Western blotting. The quantitative expression of VEGF-A, -B, and -C in eutopic endometrium from patients with endometriosis was examined throughout the menstrual cycle, and was compared to eutopic endometrial expression in control patients without endometriosis. Results: VEGF-A expression in healthy controls was lower in the secretory phase than in the proliferative phase. In patients with endometriosis, VEGF-A expression was not lower in the secretory phase than in the proliferative phase and was higher than in the secretory phase of healthy controls. The expression of VEGF-B and -C was similar to VEGF-A. The mRNA of VEGF receptors 1 and 2 was expressed at the same level in eutopic endometrium from patients with endometriosis and in healthy controls throughout the menstrual cycle. All eutopic endometrial samples from women with and without endometriosis in both the proliferative and secretory phases of the menstrual cycle showed clear bands at the expected molecular weights for VEGF-A and -B. Conclusions: These results suggest that specific angiogenic factors (VEGF-A, -B, and -C) play important roles in the pathogenesis of endometriosis.
Choi Eun-Ji,Koo Bon-Kwan,Hur Eun-Hye,Moon Ju Hyun,Kim Ji Yun,Park Han-Seung,Choi Yunsuk,Lee Kyoo-Hyung,Lee Jung-Hee,Choi Eun Kyung,Lee Je-Hwan 한국응용약물학회 2023 Biomolecules & Therapeutics(구 응용약물학회지) Vol.31 No.3
Resistance to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is a concerning problem. Polo-like kinase 1 (PLK1) is a key cell cycle modulator and is known to be associated with an activation of the PI3K pathway, which is related to the stabilization of DNA methyltransferase 1 (DNMT1), a target of HMAs. We investigated the effects of volasertib on HMA-resistant cell lines (MOLM/AZA-1 and MOLM/DEC-5) derived from MOLM-13, and bone marrow (BM) samples obtained from patients with MDS (BM blasts >5%) or AML evolved from MDS (MDS/AML). Volasertib effectively inhibited the proliferation of HMA-resistant cells with suppression of DNMTs and PI3K/AKT/mTOR and ERK pathways. Volasertib also showed significant inhibitory effects against primary BM cells from patients with MDS or MDS/AML, and the effects of volasertib inversely correlated with DNMT3B expression. The DNMT3B-overexpressed AML cells showed primary resistance to volasertib treatment. Our data suggest that volasertib has a potential role in overcoming HMA resistance in patients with MDS and MDS/ AML by suppressing the expression of DNMT3 enzymes and PI3K/AKT/mTOR and ERK pathways. We also found that DNMT3B overexpression might be associated with resistance to volasertib.
Choi, Eun-Ji,Lee, Je-Hwan,Lee, Jung-Hee,Park, Han-Seung,Ko, Sun-Hye,Hur, Eun-Hye,Moon, Juhyun,Goo, Bon-Kwan,Kim, Yeonhee,Seol, Miee,Lee, Young-Shin,Kang, Young-Ah,Jeon, Mijin,Woo, Ji Min,Lee, Kyoo-Hyu Elsevier 2018 Leukemia research Vol.68 No.-
<P><B>Abstract</B></P> <P>This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed <I>FLT3</I>-ITD-mutated AML patients. Induction regimens comprised high-dose daunorubicin (HD-DN; 90 mg/m<SUP>2</SUP>/d × 3d; n = 44), standard-dose daunorubicin (SD-DN; 45 mg/m<SUP>2</SUP>/d × 3d; n = 51), or idarubicin (IDA; 12 mg/m<SUP>2</SUP>/d × 3d; n = 33) in combination with cytarabine (100–200 mg/m<SUP>2</SUP>/d × 7d). Fifty-three patients showing persistent leukemia on interim bone marrow examination received a second course of induction chemotherapy comprising 2 days of daunorubicin (45 mg/m<SUP>2</SUP>/d) or IDA (8 or 12 mg/m<SUP>2</SUP>/d) in addition to 5 days of cytarabine. Complete remission (CR) rates were 77.3%, 56.9%, and 69.7% for HD-DN, SD-DN, and IDA, respectively (<I>P</I> = 0.101; HD-DN <I>vs.</I> SD-DN, <I>P</I> = 0.036; HD-DN <I>vs.</I> IDA, <I>P</I> = 0.453; IDA <I>vs.</I> SD-DN, <I>P</I> = 0.237). The HD-DN showed higher overall survival (OS) and event-free survival (EFS) than SD-DN and IDA: the differences between HD-DN and SD-DN (<I>P</I> = 0.009 for OS and <I>P</I> = 0.010 for EFS) were statistically significant.</P> <P>Results of <I>in vitro</I> studies using <I>FLT3</I>-ITD-mutated cell lines supported these findings. In conclusion, HD-DN improved the CR rate, OS, and EFS of <I>FLT3</I>-ITD-mutated AML patients. HD-DN also tended to yield better outcomes than IDA, though the difference was not significant. The superiority of HD-DN over IDA should be confirmed in future studies.</P> <P><B>Highlights</B></P> <P> <UL> <LI> <I>FLT3</I>-ITD-mutated AML patients benefited from high-dose daunorubicin. </LI> <LI> High-dose daunorubicin seems to yield better results than idarubicin. </LI> <LI> The results of <I>in vitro</I> studies support these findings. </LI> </UL> </P>